{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T15:04:54Z","timestamp":1763910294893,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Besides International Prognostic Index (IPI) score, baseline prognostic factors of post-transplant lymphoproliferative disorders (PTLD) are poorly identified due to the rarity of the disease. New indexes derived from healthy organ uptake in baseline 18F-FDG PET\/CT have been studied in immunocompetent lymphoma patients. The aim of this study is to evaluate the performances of the cerebellum-to-liver uptake ratio (denoted as CLIP) as a prognostic factor for PFS and OS. This retrospective multicenter study is based on patients with PTLD included in the K-VIROGREF cohort. The previously published threshold of 3.24 was used for CLIP in these analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 97 patients was included with a majority of monomorphic diffuse large B-cell lymphoma subtype (78.3%). Both IPI score (\u2265\u20093) and CLIP (&lt;\u20093.24) were significant risk factors of PFS with corresponding hazard ratios of 2.0 (1.0\u20134.0) and 2.4 (1.3\u20134.5) respectively. For OS, CLIP was not significant and resulted in a hazard ratio of 2.6 (<jats:italic>p<\/jats:italic>\u2009=\u20090.059). Neither IPI score or Total Metabolic Tumor Volume reached significance for OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CLIP is a promising predictor of PFS and perhaps OS in PTLD. Further prospective studies are needed to confirm these results.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-024-01111-8","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T13:01:51Z","timestamp":1716814911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cerebellum\/liver index on baseline 18F-FDG PET\/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-4841","authenticated-orcid":false,"given":"David","family":"Morland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukshe","family":"Kanagaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Hubel\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Kas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Ambroise","family":"Caquot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Lepr\u00eatre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Decazes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fontanet","family":"Bijou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Jacquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Chauchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Matuszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Payoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"K-VIROGREF Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Paillassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pac\u00f4me","family":"Fosse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Michel","family":"Correas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Palard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Le Cann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Ang\u00e9la","family":"Castilla-Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Guillermin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifa","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Durot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"1111_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bjh.16304","volume":"189","author":"MD Jain","year":"2020","unstructured":"Jain MD, Lam R, Liu Z, et al. Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder. Br J Haematol. 2020;189:97\u2013105. https:\/\/doi.org\/10.1111\/bjh.16304.","journal-title":"Br J Haematol"},{"key":"1111_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/ajt.14603","volume":"18","author":"VR Dharnidharka","year":"2018","unstructured":"Dharnidharka VR. Comprehensive review of post-organ transplant hematologic cancers. Am J Transplant. 2018;18:537\u201349. https:\/\/doi.org\/10.1111\/ajt.14603.","journal-title":"Am J Transplant"},{"key":"1111_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","volume":"35","author":"RU Trappe","year":"2017","unstructured":"Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. JCO. 2017;35:536\u201343. https:\/\/doi.org\/10.1200\/JCO.2016.69.3564.","journal-title":"JCO"},{"key":"1111_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13550-021-00769-8","volume":"11","author":"F Montes de Jesus","year":"2021","unstructured":"Montes de Jesus F, Dierickx D, Vergote V, et al. Prognostic superiority of international prognostic index over [18F]FDG PET\/CT volumetric parameters in post-transplant lymphoproliferative disorder. EJNMMI Res. 2021;11:29. https:\/\/doi.org\/10.1186\/s13550-021-00769-8.","journal-title":"EJNMMI Res"},{"key":"1111_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/MNM.0000000000001194","volume":"41","author":"D-H Kim","year":"2020","unstructured":"Kim D-H, Kim S-J. Diagnostic performances of F-18 FDG PET or PET\/CT for detection of post-transplant lymphoproliferative disorder: a systematic review and meta-analysis. Nucl Med Commun. 2020;41:533\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001194.","journal-title":"Nucl Med Commun"},{"key":"1111_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/diagnostics10020101","volume":"10","author":"V Ballova","year":"2020","unstructured":"Ballova V, Muoio B, Albano D, et al. Diagnostic performance of 18F-FDG PET or PET\/CT for detection of post-transplant lymphoproliferative disorder: a systematic review and a bivariate meta-analysis. Diagnostics. 2020;10:101. https:\/\/doi.org\/10.3390\/diagnostics10020101.","journal-title":"Diagnostics"},{"key":"1111_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028791","volume":"101","author":"F Godard","year":"2022","unstructured":"Godard F, Durot E, Durot C, et al. Cerebellum\/liver index in pretherapeutic 18F-FDG PET\/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance. Medicine (Baltimore). 2022;101: e28791. https:\/\/doi.org\/10.1097\/MD.0000000000028791.","journal-title":"Medicine (Baltimore)"},{"key":"1111_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s12149-021-01609-4","volume":"35","author":"D Morland","year":"2021","unstructured":"Morland D, Zizi G, Godard F, et al. 18F-FDG cerebellum\/liver index as a prognostic factor for progression-free survival in diffuse large B-cell lymphoma. Ann Nucl Med. 2021;35:785\u201393. https:\/\/doi.org\/10.1007\/s12149-021-01609-4.","journal-title":"Ann Nucl Med"},{"key":"1111_CR9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264119","author":"A Gafita","year":"2022","unstructured":"Gafita A, Calais J, Fendler WP, Eiber M. Tumor sink effect: myth or reality? J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.122.264119.","journal-title":"J Nucl Med"},{"key":"1111_CR10","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"key":"1111_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113\u201322. https:\/\/doi.org\/10.1007\/s00259-014-2705-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1111_CR12","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Cottereau A-S, Casasnovas O, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135:1396\u2013405. https:\/\/doi.org\/10.1182\/blood.2019003526.","journal-title":"Blood"},{"key":"1111_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BV, et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7: e51862. https:\/\/doi.org\/10.1371\/journal.pone.0051862.","journal-title":"PLoS ONE"},{"key":"1111_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12149-010-0415-5","volume":"24","author":"K Hanaoka","year":"2010","unstructured":"Hanaoka K, Hosono M, Shimono T, et al. Decreased brain FDG uptake in patients with extensive non-Hodgkin\u2019s lymphoma lesions. Ann Nucl Med. 2010;24:707\u201311. https:\/\/doi.org\/10.1007\/s12149-010-0415-5.","journal-title":"Ann Nucl Med"},{"key":"1111_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.913866","volume":"9","author":"D Morland","year":"2022","unstructured":"Morland D, Triumbari EKA, Maiolo E, et al. Healthy organs uptake on baseline 18F-FDG PET\/CT as an alternative to total metabolic tumor volume to predict event-free survival in classical Hodgkin\u2019s lymphoma. Front Med. 2022;9: 913866. https:\/\/doi.org\/10.3389\/fmed.2022.913866.","journal-title":"Front Med"},{"key":"1111_CR16","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.biopha.2017.01.166","volume":"88","author":"BL Viglianti","year":"2017","unstructured":"Viglianti BL, Wong KK, Wimer SM, et al. Effect of hyperglycemia on brain and liver 18 F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging. Biomed Pharmacother. 2017;88:1038\u201345. https:\/\/doi.org\/10.1016\/j.biopha.2017.01.166.","journal-title":"Biomed Pharmacother"},{"key":"1111_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","volume":"13","author":"R Trappe","year":"2012","unstructured":"Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13:196\u2013206. https:\/\/doi.org\/10.1016\/S1470-2045(11)70300-X.","journal-title":"Lancet Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01111-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-024-01111-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01111-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T13:07:05Z","timestamp":1716815225000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-024-01111-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1111"],"URL":"https:\/\/doi.org\/10.1186\/s13550-024-01111-8","relation":{},"ISSN":["2191-219X"],"issn-type":[{"type":"electronic","value":"2191-219X"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments. This study was declared and registered on the Health Data Hub (N\u00b0F20210407155710) in conformity with the reference methodology MR004 of the \u201cCommission Nationale de l'Informatique et des Libert\u00e9s\u201d, allowing the computerized management of medical data. The participants were informed of the possibility of using the information concerning them and had a right of opposition. Written informed consent was obtained from all participants. According to french law, no formal institutional review board approval or ethics committee is required for this type of study, based on patient files.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}